Recent blog posts
Mineralys Therapeutics Announces First Patient Dosed in Start-HTN, Its Second Key Trial of Lorundrostat for Hypertension Control
Latest Hotspot
3 min read
Mineralys Therapeutics Announces First Patient Dosed in Start-HTN, Its Second Key Trial of Lorundrostat for Hypertension Control
2 January 2024
Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.
Read →
Jazz Pharmaceuticals Releases Information on Stage 2 Research for Experimental JZP150 in Adults Suffering from PTSD
Latest Hotspot
3 min read
Jazz Pharmaceuticals Releases Information on Stage 2 Research for Experimental JZP150 in Adults Suffering from PTSD
2 January 2024
Jazz Pharmaceuticals plc announced early results from its Phase 2 trial evaluating the efficacy and safety of JZP150, a selective FAAH enzyme inhibitor, in adults with PTSD.
Read →
The FDA approved updated packaging for Kite Pharma's Yescarta® with survival rate information
Latest Hotspot
3 min read
The FDA approved updated packaging for Kite Pharma's Yescarta® with survival rate information
2 January 2024
The FDA has sanctioned an update to the packaging of Kite Pharma's Yescarta® treatment, now incorporating information on patient survival rates.
Read →
WAINUA™ (eplontersen) Approved in US for Adult Polyneuropathy in Hereditary Transthyretin Amyloidosis
Latest Hotspot
3 min read
WAINUA™ (eplontersen) Approved in US for Adult Polyneuropathy in Hereditary Transthyretin Amyloidosis
2 January 2024
WAINUA™ (eplontersen) Receives Groundbreaking US Sanction as a Treatment for Polyneuropathy in Adult Hereditary Transthyretin Amyloidosis Cases.
Read →
Sanofi ends tusamitamab ravtansine Phase 3 trial for 2nd-line NSCLC due to unmet primary endpoint
Latest Hotspot
3 min read
Sanofi ends tusamitamab ravtansine Phase 3 trial for 2nd-line NSCLC due to unmet primary endpoint
2 January 2024
Sanofi has terminated its study of tusamitamab ravtansine due to a Phase 3 trial in second-line NSCLC failing to achieve its main goal.
Read →
GSK has secured an exclusive licensing deal with Hansoh Pharmaceutical for the compound HS-20093
Latest Hotspot
3 min read
GSK has secured an exclusive licensing deal with Hansoh Pharmaceutical for the compound HS-20093
2 January 2024
GSK plc has entered an exclusive partnership with Hansoh Pharma to co-develop and market HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3 with a clinically proven topoisomerase inhibitor payload for serious medical conditions.
Read →
Aurinia Pharmaceuticals has formally submitted an IND application for its drug candidate AUR 200 to the FDA
Latest Hotspot
3 min read
Aurinia Pharmaceuticals has formally submitted an IND application for its drug candidate AUR 200 to the FDA
29 December 2023
Aurinia Pharmaceuticals Inc. announced it filed an IND application for AUR200 with the FDA to advance its development.
Read →
Merck Announces an Update on the U.S. Regulation Process for Gefapixant
Latest Hotspot
3 min read
Merck Announces an Update on the U.S. Regulation Process for Gefapixant
29 December 2023
Merck announced it got an FDA Complete Response Letter regarding its New Drug Application for gefapixant.
Read →
Rallybio Reveals Early Data from Phase 1 Escalating Dose Trial for RLYB116, a Novel Subcutaneous Complement 5 Blocker
Latest Hotspot
3 min read
Rallybio Reveals Early Data from Phase 1 Escalating Dose Trial for RLYB116, a Novel Subcutaneous Complement 5 Blocker
29 December 2023
Rallybio Corporation revealed early Phase 1 trial results for RLYB116, a novel drug with prolonged action and subcutaneous administration in low volumes.
Read →
Almirall Launches Initial Stage Clinical Trial for ALM223, a Modified IL-2 Fusion Protein to Treat Autoimmune Conditions
Latest Hotspot
3 min read
Almirall Launches Initial Stage Clinical Trial for ALM223, a Modified IL-2 Fusion Protein to Treat Autoimmune Conditions
29 December 2023
Almirall S.A. has recently launched a phase I clinical trial to assess the safety profile, pharmacokinetic properties, immunogenic potential, and pharmacodynamic effects of ALM223.
Read →
First participant receives dose in Tiziana Biotech's early-stage trial for nasal administered Foralumab targeting MS
Latest Hotspot
3 min read
First participant receives dose in Tiziana Biotech's early-stage trial for nasal administered Foralumab targeting MS
29 December 2023
Tiziana Life Sciences Ltd. has announced the start of a Phase 2a trial, assessing the efficacy and safety of two doses of intranasal foralumab compared to placebo in patients with non-active secondary-progressive multiple sclerosis.
Read →
NMPA Approves Review of Mabwell’s Injectable Drug 8MW0511 for Examination
Latest Hotspot
3 min read
NMPA Approves Review of Mabwell’s Injectable Drug 8MW0511 for Examination
29 December 2023
Mabwell announced the NMPA's approval of its IND application for 8MW0511, an innovative injectable recombinant fusion protein drug.
Read →